

High Throughput Gene Expression Analysis of 3D Airway Organoids

Application Note

CORNING

Hilary Sherman¹, Nathan Elliott², Andrew White², and Ann Rossi¹, Ph.D.

¹Corning Incorporated, Life Sciences, Kennebunk, ME USA;

²NanoString Technologies, Inc., Seattle, WA USA

Introduction

For over 30 years, researchers have been using permeable support systems for air-liquid interface culture to study the airway epithelium. Utilizing this traditional technique, primary airway cells are cultured on permeable supports and differentiated into ciliated, goblet, and basal cells to model lung tissue for research in toxicology and respiratory disorders, such as asthma and cystic fibrosis. There is continued need for research in these areas to identify treatments, necessitating an increase in throughput for airway models. Three-dimensional (3D) airway organoids pose a solution for modeling airway tissue. Airway organoids produced from primary airway cells have the same ability to differentiate into polarized structures consisting of ciliated, goblet, and basal cells without the need for a permeable support system¹. This allows for increased throughput of airway studies beyond the currently available 96-well format to 384-well and potentially larger formats. Importantly, advances in characterization of these model airway cultures is also critical to understanding these pathologies and facilitates high throughput cell-based assays for therapy research and development. An essential aspect of studying respiratory disorders is comparison of gene expression of healthy versus diseased tissue, as alterations in the composition of the differentiated cells or cytokines produced are often associated with various pathologies. We use the nCounter[®] PlexSet[™] assay to characterize the gene expression of airway organoids generated from healthy and asthmatic primary bronchial cells. The PlexSet assay provides a simple and cost-effective solution for multiplex sample analysis of up to 96 genes in 96 samples per run. The assay is compatible with whole cell lysate, without the need for RNA purification and was simple to incorporate into the airway organoid workflow. The result is high throughput gene expression data without amplification, cDNA conversion, or library prep.

Materials and Methods

Airway Organoid Culture

Normal and Asthmatic human bronchial epithelial cells (HBEC; Lonza Cat. Nos. CC-25405 and 00194911, respectively) were cultured in PneumaCult[™]-Ex Plus medium (STEMCELL Technologies Cat. No. 05040) per manufacturer's protocol. Cells were harvested with Accutase[®] (Corning Cat. No. 25-058-CI) and seeded onto 50 μ L of undiluted, polymerized Corning[®] Matrigel[®] matrix for Organoid Culture (Corning Cat. No. 356255) per well of a 96-well microplate (Corning Cat. No. 353219). Cells were seeded at a density of 1.4×10^4 cells per well in a volume of 80 μ L per well of assay medium. Assay medium consisted of complete

PneumaCult-ALI medium (STEMCELL Technologies Cat. No. 05001) containing 0.45 mg/mL Matrigel matrix. Medium was exchanged 3 times per week for 20 to 23 days.

Airway Organoid Staining

Organoids were collected from Matrigel matrix by pipetting up and down with Axygen[®] wide bore tips (Corning Cat. No. TF-205-WB-R-S) and incubating with Corning Cell Recovery Solution (Corning Cat. No. 354253) at 4°C for 20 minutes. Organoids were washed several times with cold phosphate buffered saline (PBS) before fixing with cold 4% paraformaldehyde for 15 minutes at 4°C. Organoids were permeabilized with 0.5% Triton X[™]-100 for 20 minutes prior to washing with PBS and staining. One microliter of primary conjugated antibody was added to each well containing 49 μ L of PBS for overnight incubation at 4°C. Airway organoids were immunolabeled with Abcam antibodies for beta IV tubulin, mucin 5AC, cytokeratin 5, and isotype control (Abcam Cat. Nos. ab204034, ab218714, ab193894, and ab199091, respectively). The next day, organoids were washed with PBS and nuclei were stained with 10 μ g/mL of Hoechst 34580 (Thermo Fisher Cat. No. H21486). Images were captured with the Thermo Fisher Scientific CellInsight[™] CX7 High-Content Screening Platform using a 40X objective.

Drug Exposure

Twenty-four hours prior to lysing organoids, media was replaced with assay medium containing 1 μ M Dexamethasone (Sigma Cat. No. D2915) or media.

Gene Expression Analysis

Samples were sent to NanoString Technologies for analysis via their nCounter platform (Figures 1 and 2). Prior to analysis, organoids were removed from Corning Matrigel matrix for Organoid




Figure 1. nCounter barcoding technology for target counting. nCounter barcoding technology uses color-coded molecular barcodes to hybridize and count nucleic acids, and is applied to analysis of RNA, DNA, and protein.




Figure 2. nCounter technology workflow. Schematic of workflow for high throughput gene expression analysis directly from cell lysates.

Culture as previously described. After organoids were separated from Matrigel matrix, they were lysed with iScript™ buffer (Bio-Rad Cat. No. 1708898) per manufacturer's protocol. Samples were immediately frozen at -80°C and shipped on dry ice for analysis. Five microliters of each lysate were hybridized with nCounter® PlexSet™ reagents for 16 hours at 67°C . Data was collected on the nCounter MAX instrument system. Digital counts were normalized to the geometric mean of internal positive control and reference gene counts, and \log_2 transformed. Reference genes ABCF1, GUSB, HPRT1, LDHA, POLR1B, and RPLP0 are commonly used by NanoString Technologies in many of their commercially available panels.

Results and Discussion

Organoid Confirmation

Within 3 days of culture, 3D structures began to appear in the wells followed by lumen formation in the center of the structures by day 17 (Figure 3). After 23 days, many of the structures had moving cilia facing the lumen that were visible via bright-field imaging at 200X. Immunofluorescence staining revealed the presence of basal cells, ciliated cells, and mucus producing cells in both normal and asthmatic organoids (Figure 4). There was more positive mucin 5AC staining with the asthmatic organoids




Figure 3. Airway Organoids. Representative photomicrographs of 3- (left), 17- (middle), and 29-day-old (right) airway organoids on Corning Matrigel matrix for organoid culture. Images were captured at 100X magnification with an EVOS® FL microscope. Scale bars are 400 μm .




Figure 4. Normal versus asthmatic airway organoids. Representative photomicrographs of 23-day-old airway organoids from normal (left) and asthmatic (right) donors. Multicolor fluorescent labels indicate specific cell types: basal cells (green), ciliated cells (red), mucus production from goblet cells (orange), nuclei (blue). Images were captured at 40X magnification. Scale bars are 100 μm .




Figure 5. Reproducibility of gene expression data from replicates. Representative correlation plot demonstrating reproducibility of counts from two different wells of the same condition.




Figure 6. Changes in expression of genes associated with airway organoid generation. Fold change of gene expression of airway organoids compared to normal HBECs. TP63 and IGA6 expression are associated with basal cells. DNAI2 and FOXP1 expression are associated with ciliated cells. MUC5AC and MUC5B expression are associated with goblet cells.




Figure 7. Fold change of gene expression in asthmatic organoids. Fold change of asthmatic organoid gene expression relative to expression in normal organoids. N = 24 from 2 independent studies.

To demonstrate high throughput gene expression analysis of diseased organoids, we compared normal and asthmatic airway organoids (Figure 7). Of note, we observed increased expression of chemokine ligand 5 (CCL5), colony-stimulating factor 3 (CSF3), interleukin 6 (IL6), interleukin 10 (IL10), interleukin receptor-like 1 (IL1RL1), mucin 5AC (MUC5AC), and phospholipase A2 (PLA2G2A) in the asthmatic organoids. These genes encode for chemokines, receptors, and other proteins associated with inflammatory processes in asthmatic airway cells⁵⁻¹¹. Finally, we were able to detect differential gene expression with the nCounter® technology between normal and asthmatic organoids (Figure 8). Generally, the subset of genes upregulated in the normal organoids are the same as those genes downregulated in asthmatic airway organoids and vice-versa. Exposure to the anti-inflammatory dexamethasone changed expression (up- and downregulation) of a greater subset of genes in the asthmatic organoids relative to the normal organoids. Taken together, the data demonstrates the feasibility

of airway organoid culture with accompanying high throughput gene expression analysis for characterization and 3D screening assays.

Conclusions

- ▶ Corning® Matrigel® matrix for organoid culture provides an ideal environment for the differentiation of bronchial epithelial cells to airway organoids.
- ▶ Corning Matrigel Matrix for organoid culture enables 3D cell culture of primary, patient-derived bronchial epithelial cells for high throughput 3D organoid research.
- ▶ Sample processing for nCounter analysis requires only cell lysis, eliminating the conventional steps for gene expression analysis (i.e., gene amplification, cDNA conversion, or library prep).
- ▶ The nCounter platform enables high throughput gene expression analysis of 3D organoid cultures for healthy and disease-model characterization and screening.




Figure 8. Fold change of gene expression of normal and asthmatic organoids in response to drug exposure. Heat map demonstrating relative gene expression of normal (left side) and asthmatic (right side) organoids, following normalization to reference genes ABCF1, GUSB, HPRT1, LDHA, POLR1B, and RPLP0 (not shown) after 24-hour exposure to DMSO control or dexamethasone. N = 24 from 2 independent studies.

References

- Danahay H, Pessotti AD, Coote J, Montgomery BE, Xia D, et al. Notch2 is required for inflammatory cytokine-driven goblet cell metaplasia in the lung. *Cell Rep* 2015;10(2):239-252. doi: 10.1016/j.celrep.2014.12.017.
- Zhao J, Maskrey B, Balzar S, Chibana K, Mustovich A, Hu H, et al. Interleukin-3-induced MUC5AC is regulated by 15-lipoxygenase 1 pathway in human bronchial epithelial cells. *Am J Respir Crit Care Med* 2009;179(9):782-790. doi: 10.1164/rccm.200811-1744OC.
- Asuero AG, Sayago A, Gonzalez AG. The correlation coefficient: an overview. *Crit Rev Anal Chem* 2006;36(1):41-59.
- Hild M, Jaffe AB. Production of 3-D airway organoids from primary human airway basal cells and their use in high throughput screening. *Curr Protoc Stem Cell Biol* 2016;37:IE.9.1-IE.9.15. doi: 10.1002/cpsc.1.
- Culley FJ, Pennycook AM, Tregoning JS, Dodd JS, Walzl G, Wells TN, et al. Role of CCL5 (RANTES) in viral lung disease. *J Virol* 2006;80(16):8151-8157. doi: 10.1128/JVI.00496-06.
- Chen G, Grotendorst G, Eichholtz T, Khalil N. GM-CSF increases airway smooth muscle cell connective tissue expression by inducing TGF- β receptors. *AM J Physiol Lung Cell Molec Physiol* 2003;284(3):L548-L556. doi: 10.1152/ajplung.00091.2002.
- Marini M, Vittori E, Hollebom J, Mattoli S. Expression of the potent inflammatory cytokines, granulocyte-macrophage-colony-stimulating factor and interleukin-6 and interleukin-8, in bronchial epithelial cells of patients with asthma. *J Allergy Clin Immunol* 1992;89(5):1001-1009.
- Yalcin AD, Bisgin A, Gorczynski RM. IL-8, IL-10, TGF-, and GCSF levels were increased in severe persistent allergic asthma patients with the anti-IgE treatment. *Mediators Inflamm* 2012;720976. doi: 10.1155/2012/720976.
- Rossios C, Pavlidis S, Hoda U, Kuo CH, Wiegman C, Russell K, et al. Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma. *J Allergy Clin Immunol* 2018;141(2):560-570. doi: 10.1016/j.jaci.2017.02.045.
- Bonser L, Erle D. Airway mucus and asthma: the role of MUC5AC and MUC5B. *J Clin Med* 2017;6(12):112. doi: 10.3390/jcm6120112.
- Mauchley, D, et al. Modulation of growth in human esophageal adenocarcinoma cells by group IIa secretory phospholipase A2. *J Thorac Cardiovasc Surg* 2010;139(3):591-599. doi: 10.1016/j.jtcvs.2009.10.061.

CORNING

Corning Incorporated
Life Sciences

836 North St.
Building 300, Suite 3401
Tewksbury, MA 01876
t 800.492.1110
t 978.442.2200
f 978.442.2476

www.corning.com/lifesciences

For more specific information on claims, visit the Certificates page at www.corning.com/lifesciences.

Warranty/Disclaimer: Unless otherwise specified, all products are for research use only. Not intended for use in diagnostic or therapeutic procedures. Corning Life Sciences makes no claims regarding the performance of these products for clinical or diagnostic applications.

For additional product or technical information, visit www.corning.com/lifesciences or call 800.492.1110. Outside the United States, call +1.978.442.2200 or contact your local Corning sales office.